Highlight
– Hormone therapy in young women with locally advanced cervical cancer treated by chemoradiotherapy reduces long-term risks of type 2 diabetes, cerebrovascular events, and skeletal fractures.
– No increased incidence of thromboembolism, breast cancer, or colorectal cancer was observed with hormone therapy.
– Hormone therapy was associated with improved overall survival during a median follow-up exceeding 11 years.
– These findings suggest hormone therapy is a safe and beneficial intervention in this undertreated population at risk of premature menopause.
Study Background
Concurrent chemoradiotherapy is the standard first-line treatment for locally advanced cervical cancer (International Federation of Gynecology and Obstetrics [FIGO] 2018 stage IIB-IVA). While effective oncologically, this treatment frequently induces premature ovarian failure, leading to early menopause in many young patients. The resultant estrogen deficiency is associated with significant long-term metabolic, skeletal, and cardiovascular morbidity, including increased risks for type 2 diabetes mellitus, osteoporosis, fractures, and cerebrovascular events. Despite international guidelines recommending consideration of hormone therapy (HT) to mitigate these risks, its use remains limited owing to concerns regarding safety, particularly fear of increased cancer recurrence or secondary malignancies. Robust long-term data on the systemic effects of HT in this specific patient group have been lacking. This study aimed to fill that critical knowledge gap by examining the association between HT commenced within the first year after chemoradiotherapy and long-term outcomes in a multinational cohort of young cervical cancer survivors.
Study Design
This work is a retrospective, multi-institutional cohort study conducted through the TriNetX electronic health record network, encompassing extensive multinational data. The study population included women under 45 years old with newly diagnosed FIGO 2018 stage IIB through IVA cervical cancer who underwent first-line concurrent chemoradiotherapy.
To reduce immortal time bias, a landmark analysis was used with the index event set at exactly one year after chemoradiotherapy initiation. Patients who died or developed any primary study outcome before this landmark were excluded. The exposure group consisted of patients who initiated estrogen-based hormone therapy within the first year post-therapy. Propensity score matching was performed to balance covariates including age at index event, current age, race, body mass index, comorbidities (Charlson Comorbidity Index), and known metastatic sites (para-aortic lymph nodes, pelvic lymph nodes, bladder, colorectal involvement).
Primary endpoints assessed were incidence of type 2 diabetes mellitus, cerebrovascular disease, osteoporosis, compression fractures, thromboembolism, breast cancer, and colorectal cancer. Overall survival was evaluated as a secondary outcome. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to compare outcomes between the HT and non-HT groups. Median follow-up times were approximately 11 years in both groups.
Key Findings
The matched cohort comprised 4,656 patients equally divided between HT recipients and non-recipients.
Hormone therapy was significantly associated with reduced incidence of multiple metabolic, skeletal, and cerebrovascular morbidities. Specifically, type 2 diabetes mellitus developed in 5.3% of HT users compared to 9.8% in non-users (HR 0.59; 95% CI, 0.32-0.81), cerebrovascular events occurred in 5.1% vs 8.9% (HR 0.71; 95% CI, 0.39-0.91), and compression fractures affected 3.1% vs 7.4% (HR 0.69; 95% CI, 0.33-0.93). Osteoporosis incidence was also lower though exact HR was not specified.
Crucially, no statistically significant increase was noted in thromboembolism, breast cancer, or colorectal cancer risk in HT users relative to non-users, alleviating a major safety concern.
Additionally, hormone therapy usage correlated with a statistically significant 19% reduction in all-cause mortality over the long-term follow-up period (HR 0.81; 95% CI, 0.63-0.91). This underscores not only the safety but also a potential survival benefit of HT in this population.
It is important to note that data on cumulative duration and discontinuation of hormone therapy during follow-up were not reliably available due to data aggregation limitations.
Expert Commentary
This study provides compelling real-world evidence supporting the safe use of estrogen-based hormone therapy in young women undergoing chemoradiotherapy for advanced cervical cancer, mitigating premature menopause consequences without compromising oncologic safety. The large multinational sample, rigorous propensity-matched design, and long median follow-up strengthen its validity.
While retrospective, the landmark analysis mitigated survival bias. The balanced adjustment for confounding clinical covariates enhances confidence that observed differences reflect HT effect rather than underlying health differences.
Biologically, estrogen replacement likely improves insulin sensitivity, lipid profiles, bone density, and endothelial function, accounting for reduced diabetes, fractures, and cerebrovascular events observed. The absence of increased breast or colorectal cancer incidence aligns with emerging understanding that menopausal HT safety depends on timing, duration, and patient selection.
Limitations include inability to analyze dose or duration effects precisely, potential residual confounding inherent to observational data, and lack of quality-of-life assessment which is critical in survivorship care. Prospective trials or registries would be beneficial to confirm findings and guide optimal HT regimens.
Conclusion
For young patients with locally advanced cervical cancer treated by chemoradiotherapy, initiating hormone therapy within the first year post-treatment is associated with significant reductions in metabolic, skeletal, and cerebrovascular complications, without increasing oncologic risk. Moreover, HT use correlates with improved overall survival over an extended period. These findings support current guideline recommendations advocating for HT in this understudied, high-risk population. Increased clinician awareness and proactive management of premature menopause with hormone therapy has the potential to greatly improve long-term health outcomes and quality of life in young cervical cancer survivors.
Funding and ClinicalTrials.gov
The original study did not specify funding sources or clinical trial registration.
References
1. Lu TF, Shih YH, Chen YF, et al. Association of Hormone Therapy with Long-Term Outcomes After Chemoradiation for Locally Advanced Cervical Cancer. Am J Obstet Gynecol. 2026 Jul 17. PMID: 42468866.
2. National Comprehensive Cancer Network. Cervical Cancer (Version 1.2024). NCCN Clinical Practice Guidelines in Oncology.
3. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015 Nov;100(11):3975-4011.
4. Simmons VN, Zeitler IC, Pilarski RT, et al. Premature menopause secondary to cancer therapy: epidemiology, etiology, treatment, and survivorship. J Natl Cancer Inst. 2018;110(8):757-763.
5. Atsma F, Bartelink ML, Grobbee DE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease: systematic review and meta-analysis. BMJ. 2017;358:j4238.
